Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.

@article{Rave2009PharmacokineticsAL,
  title={Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.},
  author={Klaus M Rave and Elizabeth Potocka and Lutz Heinemann and Tim Heise and Anders Hasager Boss and Mark J. Marino and Dolores Costello and Richard I Chen},
  journal={Diabetes, obesity & metabolism},
  year={2009},
  volume={11 7},
  pages={
          715-20
        }
}
AIM AFRESA [Technosphere Insulin (TI); MannKind Corporation, Valencia, CA], a dry powder preparation of regular human insulin (RHI), utilizes a novel and versatile drug carrier platform that enables pulmonary administration of medications typically administered by injection. The aim of this study was to compare the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of three different inhaled doses of TI with those of subcutaneous (s.c.) RHI. METHODS This randomized, open-label, four-way… CONTINUE READING
BETA

Topics from this paper.

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 35 CITATIONS

Controlled release of biologics for the treatment of type 2 diabetes.

  • Journal of controlled release : official journal of the Controlled Release Society
  • 2016
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Technosphere insulin (Afrezza): a new, inhaled prandial insulin.

  • The Annals of pharmacotherapy
  • 2015
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Pharmacokinetic characterization of the novel pulmonary delivery excipient fumaryl diketopiperazine.

  • Journal of diabetes science and technology
  • 2010
VIEW 5 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Technosphere® Insulin

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED